TET2 Deficiency Increases the Competitive Advantage of Hematopoietic Stem and Progenitor Cells through Upregulation of Thrombopoietin Receptor Signaling

Through an epigenetic drug screen, scientists discovered that inhibition of disruptor of telomeric silencing 1-like, a H3K79 methyltransferase, selectively reduced the fitness of Tet2 knockout hematopoietic stem and progenitor cells.